Complexo Hospitalario Universitario de Ferrol -ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2012

  1. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial

    Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968

2008

  1. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

  2. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4

    Journal of Viral Hepatitis, Vol. 15, Núm. 10, pp. 710-715

  3. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C

    AIDS, Vol. 22, Núm. 1, pp. 15-21

2007

  1. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients

    Journal of Acquired Immune Deficiency Syndromes, Vol. 45, Núm. 4, pp. 439-444

1997

  1. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients

    Journal of Infection, Vol. 35, Núm. 3, pp. 225-230